Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Tuberculosis

Supported pathogenM. tuberculosisMycobacterium tuberculosis

Medicines already documented

Documented evidence

Registered studies whose listed conditions mention “tuberculosis”, “mycobacterium tuberculosis”, “tb”, “latent tb”.

Show all 80

Laboratory measurements against M. tuberculosis recorded in ChEMBL.

Show all 54

Other medicines to investigate

AI prediction · nothing measured

Approved medicines with AI-predicted activity ≥40% against M. tuberculosis that are not already antimicrobials, have no registered study for this condition and have no laboratory record against it. Each shows what it is already used for. They were surfaced computationally for further investigation and are not presented as established treatments for this condition.

M. tuberculosis has 870 repurposing candidates in all. 35 are already listed above, with a registered study for this condition or a laboratory record, so the other 835 are listed here.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Every repurposing candidate for M. tuberculosis, including those with documented evidence →

Registered studies

A registration describes a study; it does not establish a positive result.

When these studies started244 of 249 have a start date · most in 2023 (19)
199420102026

  • Phase 2a Study of PBTZ169

    NCT03334734 · start 2016-12-16

    Registered record
    Registry ID
    NCT03334734
    Conditions
    Tuberculosis
    Interventions
    PBTZ169; Isoniazid
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2016-12-16
    Completion
    2018-02-22
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis
    InterventionPBTZ169; Isoniazid
    PhasePhase 2
    Registry statusTerminated

  • Evaluating Newly Approved Drugs for Multidrug-resistant TB

    NCT02754765 · start 2016-12

    Registered record
    Registry ID
    NCT02754765
    Conditions
    Tuberculosis, Multidrug-Resistant; Infection, Bacterial; Pulmonary Tuberculoses
    Interventions
    Bedaquiline; Delamanid; Clofazimine; Levofloxacin; Moxifloxacin; Linezolid; Pyrazinamide; Control arm MDR-TB regimen, consistent with WHO guidelines
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2016-12
    Completion
    2023-06
    Enrolment
    754

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis, Multidrug-Resistant; Infection, Bacterial; Pulmonary Tuberculoses
    InterventionBedaquiline; Delamanid; Clofazimine; Levofloxacin +4 more
    PhasePhase 3
    Registry statusCompleted

  • Improving the Management of Drug Resistant Tuberculosis in the UK

    NCT02875574 · start 2016-11

    Registered record
    Registry ID
    NCT02875574
    Conditions
    Tuberculosis
    Interventions
    Any treatment regimen; Bacterial mutation
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2016-11
    Completion
    2017-12
    Enrolment
    630

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis
    InterventionAny treatment regimen; Bacterial mutation
    PhaseNot recorded
    Registry statusCompleted

  • TB Host Directed Therapy

    NCT02968927 · start 2016-11

    Registered record
    Registry ID
    NCT02968927
    Conditions
    Tuberculosis
    Interventions
    Everolimus 0.5 MG; Auranofin 6 MG; Vitamin D3; CC-11050; 2HRbZE/4HRb
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2016-11
    Completion
    2020-12
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis
    InterventionEverolimus 0.5 MG; Auranofin 6 MG; Vitamin D3; CC-11050 +1 more
    PhasePhase 2
    Registry statusUnknown

  • The Correlate of Risk Targeted Intervention Study

    NCT02735590 · start 2016-09-20

    Registered record
    Registry ID
    NCT02735590
    Conditions
    Tuberculosis
    Interventions
    Isoniazid; Rifapentine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Unknown
    Start
    2016-09-20
    Completion
    2019-12-31
    Enrolment
    2,927

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis
    InterventionIsoniazid; Rifapentine
    PhasePhase 2 / Phase 3
    Registry statusUnknown

  • Evaluating the Safety, Tolerability, and Pharmacokinetics of Bedaquiline and Delamanid, Alone and in Combination, For Drug-Resistant Pulmonary Tuberculosis

    NCT02583048 · start 2016-08-15

    Registered record
    Registry ID
    NCT02583048
    Conditions
    Tuberculosis; HIV Infections
    Interventions
    Bedaquiline; Delamanid; Dolutegravir; Multidrug Background Treatment (MBT) for TB
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2016-08-15
    Completion
    2021-02-04
    Enrolment
    84

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis; HIV Infections
    InterventionBedaquiline; Delamanid; Dolutegravir; Multidrug Background Treatment (MBT) for TB
    PhasePhase 2
    Registry statusCompleted

  • Shortened Regimens for Drug-susceptible Pulmonary Tuberculosis

    NCT02901288 · start 2016-08

    Registered record
    Registry ID
    NCT02901288
    Conditions
    Tuberculosis, Pulmonary
    Interventions
    Isoniazid; Rifampicin; Pyrazinamide; Ethambutol; Levofloxacin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2016-08
    Completion
    2018-12
    Enrolment
    3,900

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis, Pulmonary
    InterventionIsoniazid; Rifampicin; Pyrazinamide; Ethambutol +1 more
    PhasePhase 4
    Registry statusUnknown

  • Impact of Once-Weekly Rifapentine and Isoniazid on the Steady State Pharmacokinetics of Dolutegravir and Darunavir Boosted With Cobicistat in Healthy Volunteers

    NCT02771249 · start 2016-06-03

    Registered record
    Registry ID
    NCT02771249
    Conditions
    HIV Infected Population With Latent Tuberculosis
    Interventions
    rifapentene (RPT); darunavir/cobicistat (DRV/c); Isoniazid (INH); Pyridoxine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2016-06-03
    Completion
    2021-08-17
    Enrolment
    37

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infected Population With Latent Tuberculosis
    Interventionrifapentene (RPT); darunavir/cobicistat (DRV/c); Isoniazid (INH); Pyridoxine
    PhasePhase 1
    Registry statusCompleted

  • VDOT for Monitoring Adherence to LTBI Treatment

    NCT02641106 · start 2016-03-08

    Registered record
    Registry ID
    NCT02641106
    Conditions
    Tuberculosis; Latent Tuberculosis Infection
    Interventions
    Video Directly Observed Therapy; In-Person DOT
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2016-03-08
    Completion
    2020-06-30
    Enrolment
    129

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis; Latent Tuberculosis Infection
    InterventionVideo Directly Observed Therapy; In-Person DOT
    PhaseNot applicable
    Registry statusCompleted

  • A 14 Day Early Bactericidal Activity Study of Nitazoxanide for the Treatment of Tuberculosis

    NCT02684240 · start 2016-02

    Registered record
    Registry ID
    NCT02684240
    Conditions
    Tuberculosis
    Interventions
    Nitazoxanide; Control
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2016-02
    Completion
    2018-04-11
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis
    InterventionNitazoxanide; Control
    PhasePhase 2
    Registry statusCompleted

  • Whole Blood Bactericidal Activity Against Mycobacterium Tuberculosis of Pyrazinamide Plus Allopurinol in Healthy Volunteers

    NCT02700347 · start 2016-02

    Registered record
    Registry ID
    NCT02700347
    Conditions
    Tuberculosis
    Interventions
    Pyrazinamide; Allopurinol
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2016-02
    Completion
    2016-04
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis
    InterventionPyrazinamide; Allopurinol
    PhasePhase 1
    Registry statusCompleted

  • TBTC Study 31: Rifapentine-containing Tuberculosis Treatment Shortening Regimens

    NCT02410772 · start 2016-01-25

    Registered record
    Registry ID
    NCT02410772
    Conditions
    Tuberculosis
    Interventions
    rifapentine; rifapentine and moxifloxacin; control
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2016-01-25
    Completion
    2021-05
    Enrolment
    2,516

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis
    Interventionrifapentine; rifapentine and moxifloxacin; control
    PhasePhase 3
    Registry statusCompleted

  • Pharmacokinetic and Pharmacodynamic Study of High-Dose Rifapentine and Moxifloxacin for Treatment of Tuberculosis

    NCT02563327 · start 2016-01-25

    Registered record
    Registry ID
    NCT02563327
    Conditions
    Tuberculosis
    Interventions
    Rifapentine; Moxifloxacin; Rifampin; Isoniazid; Pyrazinamide; Ethambutol; Pyridoxine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2016-01-25
    Completion
    2021-08-30
    Enrolment
    2,516

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis
    InterventionRifapentine; Moxifloxacin; Rifampin; Isoniazid +3 more
    PhasePhase 3
    Registry statusCompleted

  • Treatment Shortening of MDR-TB Using Existing and New Drugs

    NCT02619994 · start 2016-01

    Registered record
    Registry ID
    NCT02619994
    Conditions
    Tuberculosis, Multidrug-Resistant
    Interventions
    Linezolid; Delamanid; Levofloxacin; Pyrazinamide; Locally-used WHO-approved MDR-TB regimen in Korea
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2016-01
    Completion
    2021-06
    Enrolment
    214

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis, Multidrug-Resistant
    InterventionLinezolid; Delamanid; Levofloxacin; Pyrazinamide +1 more
    PhasePhase 2
    Registry statusCompleted

  • Preventing Childhood Tuberculosis in Lesotho (PREVENT Study)

    NCT02662829 · start 2015-12

    Registered record
    Registry ID
    NCT02662829
    Conditions
    Tuberculosis
    Interventions
    Community-based intervention; Standard of care
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2015-12
    Completion
    2019-01
    Enrolment
    562

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis
    InterventionCommunity-based intervention; Standard of care
    PhaseNot applicable
    Registry statusCompleted